Takeda and biological e. limited collaborate to accelerate access to dengue vaccine in endemic areas

Cambridge, mass. & hyderabad, india--(business wire)--takeda (tse:4502/nyse:tak) and biological e. limited (be), a leading india-based vaccines and pharmaceutical company, today announced a strategic partnership to accelerate access to qdenga®▼ (dengue tetravalent vaccine [live, attenuated]) (tak-003) multi-dose vials (mdvs). these doses will ultimately be made available for procurement by governments in endemic countries by 2030 at the latest to support national immunization programs. mdvs off.
TAK Ratings Summary
TAK Quant Ranking